The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects.
OBJECTIVE
The purpose of this split-mouth study was to evaluate the clinical response of enamel matrix proteins (EMPs, Emdogain Gel in intra-osseous defects with or without a combined application of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex).


METHODS
Twelve pairs of intra-osseous periodontal defects in 11 patients received the application of EMPs on the exposed root surface (EMP). One of the two defects received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE membrane (MEMP). At baseline, 6- and 12-month probing pocket depth (PPD), clinical attachment level (CAL) and probing bone level (PBL) were measured.


RESULTS
After 12 months, the EMP defects showed a significant mean PPD reduction of 2.86+/-0.75 mm, a mean gain in CAL of 1.28+/-2.04 mm, a mean PBL gain of 1.63+/-1.21 mm and a mean increase of recession (REC) of 1.56+/-2.30 mm. The MEMP defects showed a significant mean PPD reduction of 3.02+/-1.55 mm, a mean gain in CAL of 1.65+/-1.29 mm, a mean PBL gain of 1.58+/-1.92 mm and a mean increase of REC of 1.38+/-1.63 mm. Except for significantly more post-operative discomfort at the MEMP sites, no significant differences were found between EMP and MEMP defects.


CONCLUSIONS
Within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of CAL and PBL.
Sipos
P M
PM
Department of Periodontology, Academic Center for Dentistry Amsterdam (ACTA), 1066 EA Amsterdam, the Netherlands.
Loos
B G
BG
Abbas
F
F
Timmerman
M F
MF
van der Velden
U
U
D000293:Adolescent; D000328:Adult; D016301:Alveolar Bone Loss / Q000188:drug therapy*; D000704:Analysis of Variance; D000891:Anti-Infective Agents, Local / Q000494:pharmacology / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects*; D003746:Dental Enamel Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods*; D006801:Humans; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D019647:Oral Surgical Procedures; D010518:Periodontitis / Q000188:drug therapy; D011138:Polytetrafluoroethylene; D016037:Single-Blind Method; D018709:Statistics, Nonparametric; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000891:Anti-Infective Agents, Local; D003746:Dental Enamel Proteins; D008567:Membranes, Artificial; C109069:enamel matrix proteins; D011138:Polytetrafluoroethylene; D013752:Tetracycline